Fda accepts vertex’s supplemental new drug applications for trikafta®, symdeko® and kalydeco® for additional cftr mutations

Fda accepts vertex’s supplemental new drug applications for trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), symdeko® (tezacaftor/ivacaftor and ivacaftor) and kalydeco® (ivacaftor) for additional cftr mutations.vertex pharmaceuticals inc - fda has assigned a prescription drug user fee act (pdufa) target action date of december 30, 2020.vertex pharmaceuticals inc - more than 600 people with certain rare cf mutations could become newly eligible for trikafta, symdeko or kalydeco.
VRTX Ratings Summary
VRTX Quant Ranking